Kuros BiosciencesCSBTF 71 PB Ratio is 8.39 as of Jun. 27, 2026, which is 747% above its 10-year median of 0.99. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 89.59% on this metric.
Kuros Biosciences Ltd stock PB Ratio (=8.57) is close to 1-year low of 8.57.
The historical rank and industry rank for Kuros Biosciences's PB Ratio or its related term are showing as below:
CSBTF'
s PB Ratio Range Over the Past 10 Years
Min: 0.27 Med: 0.99 Max: 19.61
Current: 7.47
During the past 13 years, Kuros Biosciences's highest PB Ratio was 19.61. The lowest was 0.27. And the median was 0.99.
CSBTF's PB Ratio is ranked worse than 89.59% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs CSBTF: 7.47
During the past 12 months, Kuros Biosciences's average Book Value Per Share Growth Rate was 26.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -15.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Kuros Biosciences was 26.60% per year. The lowest was -50.80% per year. And the median was -19.40% per year.
Back to Basics: PB Ratio
Kuros Biosciences (OTCPK:CSBTF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Kuros Biosciences PB Ratio Related Terms
Kuros Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kuros Biosciences (CSBTF) has a PB Ratio of 8.39 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kuros Biosciences and its competitors. This is 747% above median its historical median of 0.99. Over the past decade, Kuros Biosciences' PB Ratio has ranged from 0.27 to 19.61. According to the industry distribution chart, Kuros Biosciences ranks #706 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 89.6%.
Is Kuros Biosciences' PB Ratio too high?
Kuros Biosciences' current PB Ratio of 8.39 is 747% above median its 10-year median of 0.99. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 19.61. The Medical Devices & Instruments industry median PB Ratio is 2.02. Kuros Biosciences' value of 8.39 is 315.3% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #706 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #706 out of 788 companies for PB Ratio. This places Kuros Biosciences in the lower half of its industry. The industry median PB Ratio is 2.02. Kuros Biosciences' value of 8.39 is 315.3% above this benchmark. Historically, Kuros Biosciences' own PB Ratio has ranged from 0.27 to 19.61 over the past decade. While the company's 10-year median is 0.99 vs. the industry median of 2.02, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current PB Ratio of 8.39 is 315.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current PB Ratio is 8.39, which is 747% above median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current PB Ratio is 8.39, which is 747% above median its 10-year median of 0.99 and 315.3% above the Medical Devices & Instruments industry median of 2.02. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current PB Ratio is 8.39 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
PB Ratio: 8.39 (747% above median its 10-year median of 0.99)
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
Industry Position: 315.3% above the Medical Devices & Instruments median (#706 of 788)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
